ANKTIVA Wins Wider FDA Label for Papillary Bladder Tumors
The FDA broadened ANKTIVA's indication in combination with BCG to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer, including papillary-only tumors. This is the first approval covering papillary-only BCG-unresponsive NMIBC and expands access to all patients in that setting. The decision builds on the April 2024 approval for carcinoma in situ with or without papillary tumors and is supported by data from the QUILT-3.032 trial.
ANKTIVA (nogapendekin alfa inbakicept-pmln) with BCG now has a broader FDA indication for adults whose non-muscle-invasive bladder cancer no longer responds to BCG. The update adds papillary-only disease, a group the agency had not previously covered in this setting. Papillary tumors account for roughly 85% of NMIBC cases, while NMIBC makes up about 80% of U.S. bladder cancer diagnoses.
The April 2024 clearance had covered carcinoma in situ, whether or not papillary tumors were present. Supporting evidence included QUILT-3.032 Cohort A, where 62% of 77 patients had complete response; 58% of responders lasted at least 12 months and 40% at least 24 months. Common side effects were bladder-instillation related, mostly mild to moderate.
For patients with BCG-unresponsive NMIBC and papillary-only tumors, this broader label may offer a nonsurgical option where choices were limited. It could change treatment discussions around cystectomy timing, though the label warns that delaying surgery can lead to metastatic disease. Clinicians and payers may see expanded use; patients and families could benefit from more treatment discussions, but access, cost, and safety monitoring may shape real-world impact.